S
Sue Bickerton
Researcher at AstraZeneca
Publications - 11
Citations - 139
Sue Bickerton is an academic researcher from AstraZeneca. The author has contributed to research in topics: Osimertinib & T790M. The author has an hindex of 5, co-authored 11 publications receiving 71 citations.
Papers
More filters
Journal ArticleDOI
Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRASG12C.
Jason Grant Kettle,Sharanjeet Kaur Bagal,Sue Bickerton,Bodnarchuk,Jason Breed,Rodrigo J. Carbajo,Doyle Joseph Cassar,A. Chakraborty,Sabina Cosulich,Iain A. Cumming,Michael Davies,Andrew John Eatherton,L. Evans,Lyman Feron,Shaun M. Fillery,E.S. Gleave,Frederick W. Goldberg,S. Harlfinger,Lyndsey Hanson,M.R. Howard,Rachel L. Howells,A. Jackson,Paul D. Kemmitt,J.K. Kingston,Scott G. Lamont,Hilary J. Lewis,S. Li,L. Liu,Derek Ogg,Christopher R. Phillips,Radoslaw Polanski,Graeme R. Robb,David Robinson,Sarah Ross,James M. Smith,Michael Tonge,Rebecca Whiteley,Jun Yang,L. Zhang,X. Zhao +39 more
TL;DR: Attempts to directly drug the important oncogene KRAS have met with limited success despite numerous efforts across industry and academia, and the KRASG12C mutant represents an “Achilles heel” and has ...
Journal ArticleDOI
Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I.
Nicolas Floc'h,S.M. Lim,Sue Bickerton,Afshan Ahmed,Jonathan P. Orme,Jelena Urosevic,Matthew J. Martin,Darren Cross,Byoung Chul Cho,Paul D. Smith +9 more
TL;DR: Osimertinib inhibits signaling pathways and cellular growth in G719X-mutant cell lines in vitro and demonstrate sustained tumor growth inhibition of PDX harboring the G 719X mutation alone or in combination with L861Q and S768I, which support clinical testing of osimertInib in patients with uncommon EGFR NSCLC.
Journal ArticleDOI
Islets of Langerhans from prohormone convertase-2 knockout mice show α-cell hyperplasia and tumorigenesis with elevated α-cell neogenesis
Huw B. Jones,Jaimini Reens,Simon Brocklehurst,Catherine J. Betts,Sue Bickerton,Alison L. Bigley,Richard P. Jenkins,Nicky Whalley,Derrick Morgan,David M. Smith +9 more
TL;DR: It is concluded that absolute blockade of the glucagon signal results in tumorigenesis and that the PC2‐ko mouse represents a valuable model for investigation of islet tumours and pancreatic ductal neogenesis.
Journal ArticleDOI
Pharmacological validation of a telemetric model for the measurement of bronchoconstriction in conscious rats
Lorna Ewart,Michael J. Haley,Sue Bickerton,Jonathan Bright,Katherine Elliott,Alan McCarthy,Lisa Williams,Sally-Ann Ricketts,Tom Holland,Jean-Pierre Valentin +9 more
TL;DR: Airway resistance in conscious, instrumented rats was compared to measurement in anaesthetised rats via a fluid filled oesophageal catheter following administration of two different pharmacological agents.
Journal ArticleDOI
Analytic evaluation of a human ELISA kit for measurement of inhibin B in rat samples.
Michelle Coulson,Sue Bickerton,Catherine J. Betts,Matt Jacobsen,Jane Stewart,Robert E. Chapin,William J. Reagan,James D. Alvey,Zoltan Erdos,Louise Parks Saldutti,Manisha Sonee,Nancy Bogdan,Monica Singer,Petra Vinken,Valerie Barlow,Karen Czajkowski,James H. Kim +16 more
TL;DR: In this paper, a cross-laboratory analytic evaluation of a commercially available human inhibin B ELISA for measuring inhibin b in rat serum and plasma has been undertaken, and the results showed that the ELISA meets the analytical performance criteria; however, precision at the low end of the standard curve, biological variability, and low control values observed in some laboratories indicate that the utility of the assay may be limited in some labs.